Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0009922814533412 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unusual Cause of Mid Myocardial Late Gadolinium Enhancement at Cardiac MRI.
Radiol Cardiothorac Imaging
February 2025
From the Department of Radiology, Narayana Institute of Cardiac Sciences, Bangalore 560099, India (S.G., V.R.); and Department of Radiology, Amrita Institute of Medical Sciences and Research Centre, Kochi, India (R.R.).
Cardiac MRI is the reference standard for identifying and evaluating myocardial pathologic conditions. Late gadolinium enhancement characteristics provide an excellent guide in classifying disease and triaging patients. Anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA) is an uncommon congenital anomaly.
View Article and Find Full Text PDFNeonatal T cells unleash innate powers to combat congenital cytomegalovirus infection.
J Clin Invest
January 2025
Approximately 1 in 200 newborns worldwide are affected by congenital cytomegalovirus (CMV). Most of these cases are asymptomatic due to successful control of the infection by the newborn's immune system. In this issue of the JCI, Semmes et al.
View Article and Find Full Text PDFA vaccine against cytomegalovirus: how close are we?
J Clin Invest
January 2025
Department of Pediatrics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
The pursuit of a vaccine against the human cytomegalovirus (HCMV) has been ongoing for more than 50 years. HCMV is the leading infectious cause of birth defects, including damage to the brain, and is a common cause of complications in organ transplantation. The complex biology of HCMV has made vaccine development difficult, but a recent meeting sponsored by the National Institute of Allergy and Infectious Diseases in September of 2023 brought together experts from academia, industry, and federal agencies to discuss progress in the field.
View Article and Find Full Text PDFA Prospective, Noninterventional Study to Evaluate the Impact of Emicizumab in the Management of Hemophilia A.
Cureus
December 2024
Department of Medicine, Assam Medical College and Hospital, Dibrugarh, IND.
Background and objective Hemophilia A (HA) is a genetic bleeding disorder caused by a lack of factor VIII (FVIII) and is associated with frequent bleeding and joint damage. Traditional intravenous treatments for this condition are cumbersome and can lead to complications. Emicizumab, a bispecific monoclonal antibody, offers a promising subcutaneous alternative with potential safety and efficacy-related benefits.
View Article and Find Full Text PDFLong-term outcome, mortality predictors and cardiac-device related infective endocarditis in patients with surgically corrected valvular versus non-valvular heart failure treated with cardiac resynchronization therapy.
Kardiol Pol
January 2025
Department of Cardiology, Division of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Silesian Center for Heart Diseases, Zabrze, Poland.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!